Who Owns Zimmer Biomet?

Is Zimmer Biomet publicly traded?
Yes. Zimmer Biomet Holdings, Inc. trades on the New York Stock Exchange under the ticker symbol ZBH. The company is also listed on the SIX Swiss Exchange. Zimmer Biomet is a component of the S&P 500 index. The company was first spun off from Bristol Myers Squibb in August 2001 and has been independently traded since then.

When was Zimmer Biomet founded?
Zimmer Biomet traces its origins to 1927, when Justin O. Zimmer founded Zimmer Manufacturing Company in Warsaw, Indiana, to produce aluminum splints. The modern Zimmer Biomet Holdings, Inc. was incorporated in Delaware in 2001 and was formed through the acquisition of Biomet, Inc. in June 2015, at which point the company changed its name from Zimmer Holdings, Inc. to Zimmer Biomet Holdings, Inc.

Where is Zimmer Biomet headquartered?
Zimmer Biomet is headquartered at 345 East Main Street, Warsaw, Indiana 46580, USA. Warsaw, Indiana, is a major hub for the orthopedic device industry, with Zimmer Biomet as one of its anchor companies. The company operates manufacturing and distribution facilities across the United States, Europe, Asia, and Latin America.

What products does Zimmer Biomet make?
Zimmer Biomet manufactures orthopedic reconstructive products (knee, hip, shoulder, elbow replacements), sports medicine and biologics products, extremities and trauma products, craniomaxillofacial and thoracic products, bone cement, surgical products, and integrated digital and robotic technologies. Key product platforms include ROSA Robotic Solutions, Persona OsseoTi Keel Tibia, Oxford Cementless Partial Knee, Z1 Femoral Hip System, and iTaperloc Complete and iG7 Hip System with iodine-treated implants.

What are Zimmer Biomet's major acquisitions?
Zimmer Biomet's most significant acquisition was Biomet, Inc. in June 2015 for approximately $14.0 billion, which created the current company. Other major acquisitions include Centerpulse AG (2003, $3.2 billion), LDR Holding Corporation (2016, $1 billion), Paragon 28 (April 2025, $1.2 billion), OrthoGrid Systems (2024), Monogram Technologies (2025), and the iovera pain therapy business from Pacira BioSciences (2026, $140 million).

What is ZimVie?
ZimVie Inc. (NASDAQ: ZVIE) is an independent public company that was spun off from Zimmer Biomet in March 2022. ZimVie operates Zimmer Biomet's former spine and dental business. The spin-off allowed Zimmer Biomet to focus on its core orthopedic reconstructive and sports medicine businesses. ZimVie is no longer part of Zimmer Biomet.

Who is the CEO of Zimmer Biomet?
Ivan Tornos serves as Chairman, President, and CEO of Zimmer Biomet. Tornos was appointed CEO in 2023, succeeding Bryan Hanson. Under Tornos's leadership, the company has focused on its "Magnificent Seven" innovation platforms, completed three transformative acquisitions, and initiated a transition to a direct sales model in the U.S.

What is Zimmer Biomet's revenue?
Zimmer Biomet reported FY2025 (ended December 31, 2025) net sales of $8.23 billion, up 7.2% from $7.68 billion in FY2024. Net earnings were $705.1 million, and adjusted net earnings were $1.63 billion. Diluted EPS was $3.55, and adjusted diluted EPS was $8.20. For Q1 2026, net sales were $2.09 billion, up 9.3%, with net earnings of $238.1 million and diluted EPS of $1.22.